Αρχική World News EMA Adopts a New Pharmaceutical Form of Selumetinib World News EMA Adopts a New Pharmaceutical Form of Selumetinib Από Ogkologos - 16 Δεκεμβρίου, 2025 518 0 Facebook Twitter Google+ Pinterest WhatsApp It is associated with an extension to the existing indication Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Mom Battling Breast Cancer And Daughter With Alopecia Pose Together To... 7 Νοεμβρίου, 2019 New ESMO Framework to Resolve Uncertainties About the De-intensification of Cancer... 9 Μαΐου, 2022 Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk... 30 Μαρτίου, 2026 Higher Risk of Invasive Behaviour for Oncogenic Fusions–Driven Paediatric Thyroid Cancers 21 Ιανουαρίου, 2022 Φόρτωση περισσοτέρων HOT NEWS Molecular Profiling Identifies Targetable Alterations in Majority of Patients with Advanced... First immunotherapy approved for cervical cancer in England and Scotland Shortening Duration of Adjuvant Treatment from 6 to 3 Months Did... Opinion: ‘We can’t afford to stop now’